has been cited by the following article(s):
[1]
|
Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated review
Reviews in Medical Virology,
2022
DOI:10.1002/rmv.2321
|
|
|
[2]
|
Targeting K-Ras Mutations Show Promise Towards Ending Ras’s
“Undruggable” Era
Protein & Peptide Letters,
2022
DOI:10.2174/0929866529666221003124202
|
|
|
[3]
|
Targeting K-Ras Mutations Show Promise Towards Ending Ras’s
“Undruggable” Era
Protein & Peptide Letters,
2022
DOI:10.2174/0929866529666221003124202
|
|
|
[4]
|
Rho GTPases: Promising candidates for overcoming chemotherapeutic resistance
Cancer Letters,
2020
DOI:10.1016/j.canlet.2020.01.018
|
|
|
[5]
|
Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges
Cells,
2019
DOI:10.3390/cells8030255
|
|
|